Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody.

Authors

null

Christopher McCudden

Dept. of Pathology & Lab. Medicine, The Ottawa Hospital University of Ottawa, Ottawa, ON, Canada

Christopher McCudden , Amy Axel , Dominique Slaets , Sandy Frans , Jaime Bald , Jordan Mark Schecter , Tahamtan Ahmadi , Torben Plesner , Kate Sasser

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8590)

DOI

10.1200/jco.2015.33.15_suppl.8590

Abstract #

8590

Poster Bd #

408

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.

Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.

First Author: Joaquin Martinez-Lopez

Poster

2019 ASCO Annual Meeting

Minimal residual disease clinical monitoring and depth of response in multiple myeloma.

Minimal residual disease clinical monitoring and depth of response in multiple myeloma.

First Author: Joaquin Martinez-Lopez